This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday By Benzinga

Benzinga – by Avi Kapoor, Benzinga Staff Writer.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price target of $31. ACADIA Pharmaceuticals shares fell 0.6% to close at $15.50 on Wednesday. See how other analysts view this stock.
Mizuho analyst Wei Fang initiated coverage on Grab Holdings Limited (NASDAQ:GRAB) with an Outperform rating and announced a price target of $5. Grab shares fell 0.3% to close at $3.51 on Wednesday. See how other analysts view this stock.
Redburn Atlantic analyst Steve Chesney initiated coverage on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a Buy rating and announced a price target of $545. Vertex Pharmaceuticals shares rose 0.1% to settle at $474.00 on Wednesday. See how other analysts view this stock. See how other analysts view this stock.
Stephens & Co. analyst Mason Carrico initiated coverage on Hologic, Inc. (NASDAQ:HOLX) with an Overweight rating and announced a price target of $87. Hologic shares gained 0.9% to close at $72.27 on Wednesday. See how other analysts view this stock.
Oppenheimer analyst Ian Zaffino initiated coverage on Kyndryl Holdings, Inc. (NYSE:KD) with an Outperform rating and announced a price target of $33. Kyndryl shares fell 1% to settle at $25.28 on Wednesday. See how other analysts view this stock.

Check This Out: Over $30M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

Latest Ratings for VRTX

DateFirmActionFromTo

Feb 2022	RBC Capital	Downgrades	Outperform	Sector Perform
Jan 2022	BMO Capital	Upgrades	Market Perform	Outperform
Dec 2021	Wells Fargo	Initiates Coverage On		Overweight